TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Gastrointestinal late effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Maximal Isokinetic Knee Extensor Torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Nodule Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with PEFR >= 70% predicted normal value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Successful hospital discharge at three days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Safety of the combination of alemtuzumab and bendamustine
Endpoint domain: Adverse events/effects
Primary endpoint: single nucleotide polymorphism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Neutrophil Count (ANC) of 500/uL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: appearance of intestinal sounds postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of binary responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Allergic reactions to wine
Endpoint domain: Adverse events/effects
Primary endpoint: Change of Serum Endostatin Level (ng/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of eGFR Level (mL/Min/1.73m^2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in airway fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuing Study Therapy Due to an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of radiation respiratory events or esophagitis with grade 3 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: HKA angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of bleeding due to surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-Emergent Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of Treatment Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Safety assessment through adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Telemetry monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed concentration (Cmax) of Selpercatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Lower Extremity Muscle Strength- Extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Lower Extremity Muscle Strength- Flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Lower Extremity Muscle Strength- Hip Posterolateral Stabilizer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Mobility- Timed Stair Climb Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mobility- Forward Step-Down Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3 and 4 thrombocytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Moderato Pacing Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderato Pacing Safety
Endpoint domain: Adverse events/effects
Primary endpoint: Hypertension Treatment Phase Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypertension Treatment Phase Safety
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Intrinsic Ventricular Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anesthesia efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of a pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Mean Change in Massachusetts General Hospital Hairpulling Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI RAMRIS Erosion Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 44 Joint Disease Activity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall response rate (CR+PR) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in impairment of emotional and behavioural symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety and tolerability of BCV
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in % body weight at the end of a 16 week period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in body fat at the end of 16 week period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in lipid panel results at end of 16 week period (total cholesterol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Visual Numeric Scale (VNS) for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of subjects who complete the study
Endpoint domain: Mortality/survival
Primary endpoint: incidence and event rates of hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Convergence Insufficiency Symptom Survey score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visual comfort scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in mean levels of depression and anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: distal phalangeal bone erosion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of Ventilator-Related Pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Candidate biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Structural changes of subcutaneous tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Montgomery Asberg Depression Rating Scale, MADRS-S
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Goal Processing Scale Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Urine Uric Acid Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Number of Participants With Urine Uric Acid Precipitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intraocular pressure (IOP) spikes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Mean Change in Disease Activity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modification of glycemic profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Angiogenic Factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Shoulder Value score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Procollagen N-terminal Peptide 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procollagen III N-Terminal Peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Galectin 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ROTEM platelet variations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: PFA variations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in the RLS Symptom Severity at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Responding to Treatment at Week 12
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With Augmentation
Endpoint domain: Adverse events/effects
Primary endpoint: cellular and humoral immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of Nonpsychotic Behavioral Side Effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with a First Episode of Vaccine-Type Acute Otitis Media (VT-AOM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants with Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Venous thromboembolic events (VTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mechanical ventilation free-survival
Endpoint domain: Mortality/survival
Primary endpoint: Out-of-hospital death not attributed to major injury
Endpoint domain: Mortality/survival
Primary endpoint: Toxicity of radiotherapy and Triapine® combination therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of Triapine®
Endpoint domain: Adverse events/effects
Primary endpoint: Smoking Abstinence at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Response Rate (ORR) in Cohort 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Surgery Pain Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardio-ankle vascular index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Geometric mean folds increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Levine-Katz Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in fMRI BOLD Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants That Experience At Least One Treatment-Emergent Adverse Event (TEAE) Post-Dose
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Markedly Abnormal Clinical Laboratory Results Post-Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Markedly Abnormal Vital Signs Post-Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Markedly Abnormal Electrocardiogram (ECG) Findings Post-Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes of the New Freezing of Gait Questionnaire (NFOGQ) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in knowledge about diabetes and its treatments
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in levels of SFK protein activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Technical Success of Device Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: RMS error during registration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Position of the performed osteotomies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from baseline in self-reported symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in functional impairment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Treatment Emergent Adverse Events by System Organ Classification and Preferred Term
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentration profile of gefapixant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of maxCBFV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acute Radiation Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Unstable angina with ECG changes or raised levels of cardiac markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in SUCCAB performance (accuracy/reaction time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to augmented web-base physiotherapy programme
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Participant safety - adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of endometriosis-associated ovarian carcinomas
Endpoint domain: Mortality/survival
Primary endpoint: clinical outcome of endometriosis-associated ovarian carcinomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in thoracic rotation mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity in the dlPFC during the training-session
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of response for increase from baseline of hemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Patients Who Had Response by RECIST Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Vital signs (BP and HR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Root proximity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Waist circumference: Number of participants above the recommended level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Wash-In Slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Transit Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success in Terms of the Merle D'Aubigne Postel Score for Pain Category
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success in Terms of the Merle D'Aubigne Postel Score for Walk Category
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success in Terms of the Merle D'Aubigne Postel Score for Mobility Category
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difficult mask ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Recalcitrant symptoms of chronic rhinitis or chronic urticaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment entry
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: neurovascular risk factors for foot ulceration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Area under the curve for carotenoids, phylloquinone, tocopherols, and retinyl palmitate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: minimal knee extension in stance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prediction accuracy of cardiovascular disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prediction accuracy of metabolic disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: arterial blood pressure response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Non-progression Rate at 2 Months
Endpoint domain: Mortality/survival
Primary endpoint: Number of comorbidities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Percent Excess Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of MACE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adverse effects of the treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Effect of the treatment
Endpoint domain: Physiological/clinical
Primary endpoint: Health Belief
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HPV information
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Biomechanical measures of postural control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of genetic variants in cases versus controls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in white adipose tissue mitochondrial respiration at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in indirect calorimetry at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes from baseline in body composition at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Motor manifestations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number and severity of TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: serum hyaluronic acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DLT incidence and frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Bacterial load in sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Thyroglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: ECG outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Laboratory outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical exam outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of electronic orders entered
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety and tolerability of SB-728-T cells infusion
Endpoint domain: Adverse events/effects
Primary endpoint: rate of transfer to the intensive care unit (ICU)
Endpoint domain: Adverse events/effects
Primary endpoint: Low bone mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevalence of toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Pathological Complete Response (pCR) Plus Near Complete Response (npCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in characteristics and frequency of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Position of intubation probe
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Developmental scores by BSID-III
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year portal/superior mesenteric vein stenosis free survival
Endpoint domain: Mortality/survival
Primary endpoint: Progression of rheumatic heart disease valve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adherence to BPP
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Identification of prostate cancer foci
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement on the Oswestry Disability Index (ODI) scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Colorectal cancer screening utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: PROMIS pain score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: PROMIS Physical Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PROMIS Global Health
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Compliance and activity Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Global Assessment of Change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self Reported Assessment of Sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Renin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Signs of Anxiety and Depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Levels of subjective sensation related to Hyperventilation Syndrome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Breath-holding time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of systemic reactions
Endpoint domain: Adverse events/effects